New drug HBI-2376 targets Hard-to-Treat cancers in early trial
NCT ID NCT05163028
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new oral drug called HBI-2376 in about 42 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS or EGFR mutations and have stopped responding to standard treatments. The main goals are to find a safe dose and understand how the drug moves through the body. It is not yet known if the drug will shrink tumors or improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBI-2376 (a SHP2 inhibitor drug)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced cancers that have KRAS or EGFR mutations and have not responded to standard therapies.
What could go wrong
This is a very early (Phase 1) trial with only 42 participants, focused on safety and dosing, not on proving the drug works. Many drugs fail at this stage, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BRCR Medical Center
Plantation, Florida, 33322, United States
-
California Cancer Associates for Research and Excellence, Inc. (cCare)
Encinitas, California, 92024, United States
-
California Cancer Associates for Research and Excellence, Inc. (cCare)
San Marcos, California, 92069, United States
-
City of Hope
Duarte, California, 91010, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
Orlando Health, Inc.
Orlando, Florida, 32806, United States
-
Pan American Center for Oncology Trials (PanOncology Trials)
Rio Piedras, Puerto Rico, 00935, Puerto Rico
-
Providence Medical Foundation
Fullerton, California, 92835, United States
-
Sarcoma Oncology
Santa Monica, California, 90403, United States
-
Texas Oncology - Tyler
Tyler, Texas, 75702, United States
-
UCLA Hematology/Oncology
Santa Monica, California, 90404, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States